pilsicainide has been researched along with Atrioventricular Conduction Block in 1 studies
pilsicainide: structure given in first source
pilsicainide : A secondary carboxamide resulting from the formal condensation of the amino group of 2,6-dimethylaniline with the carboxy group of (tetrahydro-1H-pyrrolizin-7a(5H)-yl)acetic acid. It is a sodium channel blocker which is used as an antiarrhythmic drug for the management of atrial tachyarrhythmias in Japan.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pharmacokinetics of pilsicainide transdermal patch and its electropharmacological effects were simultaneously assessed using chronic atrioventricular block dogs." | 7.75 | Simultaneous assessment of pharmacokinetics of pilsicainide transdermal patch and its electropharmacological effects on atria of chronic atrioventricular block dogs. ( Iwasaki, H; Nagai, T; Nakamura, Y; Satoh, Y; Shinkai, N; Sugiyama, A; Takahara, A, 2009) |
| "Pharmacokinetics of pilsicainide transdermal patch and its electropharmacological effects were simultaneously assessed using chronic atrioventricular block dogs." | 3.75 | Simultaneous assessment of pharmacokinetics of pilsicainide transdermal patch and its electropharmacological effects on atria of chronic atrioventricular block dogs. ( Iwasaki, H; Nagai, T; Nakamura, Y; Satoh, Y; Shinkai, N; Sugiyama, A; Takahara, A, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iwasaki, H | 1 |
| Takahara, A | 1 |
| Nakamura, Y | 1 |
| Satoh, Y | 1 |
| Nagai, T | 1 |
| Shinkai, N | 1 |
| Sugiyama, A | 1 |
1 other study available for pilsicainide and Atrioventricular Conduction Block
| Article | Year |
|---|---|
Simultaneous assessment of pharmacokinetics of pilsicainide transdermal patch and its electropharmacological effects on atria of chronic atrioventricular block dogs.
Topics: Administration, Cutaneous; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Bl | 2009 |